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Abstract: The identification of endothelial progenitor cells (EPCs) has led to a significant paradigm in the field of vascu-
lar biology and opened a door to the development of new therapeutic approaches. Based on the current evidence, it ap-
pears that EPCs may make both direct contribution to neovascularization and indirectly promote the angiogenic function 
of local endothelial cells via secretion of angiogenic factors. This concept of arterial wall repair mediated by bone marrow 
(BM)-derived EPCs provided an alternative to the local “response to injury hypothesis” for development of atherosclerotic 
inflammation. Increased oxidant stress has been proposed as a molecular mechanism for endothelial dysfunction, in part 
by reducing nitric oxide (NO) bioavailability. EPCs function may also be highly dependent on a well-controlled oxidant 
stress because EPCs NO bioavailability (which is highly sensitive to oxidant stress) is critical for their in vivo function. 
The critical question is whether oxidant damage directly leads to an impairment in EPCs function. It was revealed that ac-
tivation of angiotensin II (Ang II) type 1 receptor stimulates nicotinamide-adenine dinucleotide phosphate (NADPH) oxi-
dase in the vascular endothelium and leads to production of reactive oxygen species. We observed that Ang II accelerates 
both BM- and peripheral blood (PB)-derived EPCs senescence by a gp91phox-mediated increase of oxidative stress, re-
sulting in EPCs dysfunction. Consistently, both Ang II receptor 1 blockers (ARBs) and angiotensin converting enzyme 
(ACE) inhibitors have been reported to increase the number of EPCs in patients with cardiovascular disease. In this re-
view, we describe current understanding of the contributions of oxidative stress in cardiovascular disease, focusing on the 
potential mechanisms of EPCs senescence. 
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INTRODUCTION 
  The identification of endothelial progenitor cells (EPCs) 
has led to a significant paradigm shift in the field of vascular 
biology. It has become evident that bone marrow (BM)-
derived circulating EPCs can contribute to and amplify 
neovascularization. EPCs significantly contribute to adult 
vessel formation by physically incorporating and promoting 
vessel growth by paracrine mechanisms [1, 2]. It is believed 
that the majority of EPCs originate in the BM. The odyssey 
from BM to vascular endothelium can be divided into three 
stages. First, EPCs are mobilized or released from BM into 
systemic circulation in response to specific stimuli (mobili-
zation). A number of cytokines and growth factors appear to 
promote this step. Subsequently, the cells appear to home to 
preferentially to sites of tissue injury (homing). Finally, 
some EPCs are incorporated into new blood vessels formed 
by the extension of existing vessels (angiogenesis) or possi-
bly formed in situ (vasculogenesis). The concept of arterial 
wall repair mediated by BM-derived EPCs provided an al-
ternative to the local “response to injury hypothesis” for the 
development of atherosclerotic inflammation. Based on the 
current evidence, it appears that EPCs may directly contrib-
ute to neovascularization and indirectly promote the angio-
genic function of local endothelial cells via secretion of an-
giogenic factors. According to this new theory, the arterial 
wall can deal fairly well with multiple circulating and local  
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noxious stimuli, as long as the BM-derived repair capacity, 
which induces competent EPCs and probably progenitors of 
other lineages, remains intact. Circulating EPCs are also in-
dicators of overall cardiovascular health. Vasa et al. [3] ini-
tially showed that levels of circulating EPCs (CD34/kinase 
insert domain receptor (KDR)-positive) are higher in healthy 
volunteers than in patients with coronary artery disease. Hill 
et al. [4] analyzed “colony-forming units” of EPCs and 
found that this measurement negatively correlated with 
Framingham risk factor score. They also found that a reduc-
tion in EPCs colonies was a good predictor of impairment in 
flow-mediated brachial-artery reactivity. In a related study, it 
was reported that EPCs isolated from patients with type 2 
diabetes mellitus display impaired proliferation and reduced 
incorporation into tube-like structures on Matrigel [5]. Con-
versely, statin (HMG-CoA reductase inhibitor) therapy in-
creases circulating EPCs levels in patients with coronary 
artery disease [6]. Futhermore, an age-dependent decrease in 
EPCs mobilization has been reported [7]. Several of coro-
nary risk factors are clustered in patients with cardiovascular 
disease. All of these risk factors are also associated with ele-
vated markers of reactive oxygen species (ROS) [8].  
  The tissue microenvironment after ischemia is character-
ized by excessive production of ROS and oxidized metabo-
lites. Prior studies have demonstrated that oxidative stress 
directly contributes to endothelial dysfunction and vascular 
disease [9-12]. These observations suggest that EPCs, in 
contrast to mature endothelial cells, are uniquely equipped 
with antioxidant defence systems to resist ROS-driven cyto-
toxicity if they are active participants in various repairs in 
ischemic tissues. Recently, two in vitro studies demonstrated 276 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Imanishi et al. 
that EPCs express higher levels of manganese superoxide 
dismutase (MnSOD) and glutathione peroxidase-1 (GPx-1) 
[13, 14]. It has also been shown that the collective inhibition 
of catalase, MnSOD, and GPx-1 increases ROS levels in 
EPCs and that this inhibition impairs EPCs survival and mi-
gration [15]. In fact, some studies have suggested that EPCs 
may be resistant to oxidative stress [15, 16]. Dernbach et al.
[16] reported that EPCs are resistant to oxidative stress and 
uniquely equipped to repair damaged vessels in ischemic 
tissues. Some controversy does exist about the effects of 
oxidative stress on EPCs. Ingram et al. [17] reported that 
EPCs exhibited increased apoptosis and diminished tube-
forming ability in vitro and in vivo in response to oxidative 
stress, which was directly linked to activation of a redox-
dependent stress-induced kinase pathway. The current re-
view describes the characterstics and properties of EPCs, 
focusing on the effects of oxidative stress on EPCs senes-
cence. 
EPCs DEFINITION AND CHARACTERIZATION 
  The ability of the BM to give rise to endothelial cells was 
first reported by Asahara et al [1]. This study was based on 
the finding that EPCs circulating in peripheral blood (PB) 
express the hematopoietic marker CD34. The EPCs were 
defined as cells positive for both hematopoietic stem cells 
and endothelial cell markers, such as CD34 and vascular 
endothelial growth factor (VEGF) receptor-2, respectively. 
The latter VEGF receptor-2 is often referred to as KDR. 
 The  putative  CD34
+ EPCs are able to proliferate and dif-
ferentiate to mature endothelial cells with expression of dif-
ferent endothelial markers such as KDR [2, 18], platelet-
endothelial cell adhesion molecule (CD31) [2, 15], von 
Willebrand factor [2, 18, 20], VE-cadherin [2, 18], caveolin-
1 [19, 21], and endothelial nitric oxide (NO) synthase 
(eNOS) [19, 21]. While in vitro, EPCs can form vascular-
like structures [18, 21], and in vivo, incorporate into neoves-
sels at sites of tissue ischemia [18, 20, 22]. Of note, CD34 
antigen density is the highest on early progenitors and de-
creases progressively as the cells mature [23]; however, 
CD34 is expressed not only on EPCs but on mature endothe-
lial cells, albeit at a lower density [24]. As noted, it remains 
to be determined whether or not CD34
+/KDR
+ cells fully 
reflect changes in EPCs capable of arterial repair and angio-
genic activity [25]. Therefore, an early hematopoietic stem 
cells marker, CD133, was adopted as an alternative addi-
tional marker to indicate a “true” EPCs [26, 27]. In the pre-
sent time, EPCs are thought to be a heterogenous population 
consisting of a more primitive CD133
+/CD34
+/VEGFR-2
+
subpopulation and a more mature CD133
-/CD34
+/VEGFR-2
+
subpopulation. The marker CD133 (also known as AC133) 
is a 120-kDa transmembrane polypeptide with as yet un-
known biological function. It is expressed on hematopoietic 
stem cells and progenitor cells from human BM, fetal liver, 
and peripheral blood (PB) [28]. As progenitors develop to 
more mature endothelium-like cells, CD133 is rapidly down-
regulated [27]. The CD133
+ cells are able to form both early 
and late outgrowing colonies [27]. Thus, CD133 might pro-
vide a more reliable means of defining and tracking human 
angioblast-like EPCs and distinguishing these from mature 
endothelial or monocytic cells. Recently, Friedrich et al. [29]  
have demonstrated that CD34
- /CD133
+/ VEGFR-2
+ EPCs 
are precursors of CD34
+/CD133
+/VEGFR-2
+ EPCs with a 
higher potential for vascular repair. These data extend cur-
rent knowledge about the heterogenous EPCs population and 
may have implications for the treatment of vascular disease 
and arterial injury. Several recently published data suggested 
that other populations of BM-derived, circulating, or tissue 
resident cells might also possess properties of EPCs. In par-
ticular, these sub-populations were characterized by expres-
sion of monocyte marker CD14, together with CD34 or 
VEGFR-2 [30, 31]. Furthermore, “early” isolated EPCs also 
displayed expression of monocyte marker (CD14, CD11b, 
CD11c),whereasthe“late” endothelial outgrowth was CD14-
negative and strongly expressed markers of mature endothe-
lial cells [32, 33]. Hence, the definition of EPCs become 
more universal and indeed encompass rather heterogenous 
cell sub-populations of multiple origins and localization, 
which finally differentiate into functionally active mature 
endothelial cells. Despite the multiple EPCs origin, common 
characteristics of EPCs remain the expression of stem/ pro-
genitor marker, their clonogenic potential (i.e. the formation 
of colony-forming units) and proliferative capacity (i.e. the 
development of late high-proliferative endothelial out-
growth). 
  Considering the growing importance of the EPCs colo-
nies in cardiovascular research, it is crucial to investigate the 
characteristics of the EPCs colony in detail. There are at least 
2 morphological and functionally distinct endothelial cell 
populations in circulating MNCs [2]. The early spindle-like 
outgrowth cells possess a relatively low proliferative capac-
ity and low ability to express mature endothelial proteins 
[18]. These cells presumably represent cells of different line-
age, which include a subset of CD14
+/CD34
- monocytic 
cells, which have the potential to differentiate (transdifferen-
tiate) into endothelial-like cells under certain environmental 
condition in the presence of special growth factors (e.g., 
VEGF, fibroblast growth factor, and so on) [34]. Late “out-
growth cells” show a high proliferative potential and origi-
nate predominantly from BM donors and are considered as 
circulating angioblasts [2]. It is important to appreciate that 
although monocyte-derived EPCs have a lower in vitro pro-
liferation potential than hematopoietic stem cells or cord 
blood-derived EPCs [35], the different progenitor types seem 
to have a similar ability to enhance neovascularization in 
experimental models [18, 36, 37]. One may speculate that 
proliferation capacity is not the decisive factor and that the 
reduced proliferation of the monocyte-derived EPCs is likely 
to be attributable to increased release of growth factors, 
which may act in a paracrine manner to support angiogenesis 
and arteriogenesis [38]. Hur et al. [39] have found that a 
specific subset of T cells (CD3
+CD31
+CXCR4
+) make up the 
central cluster of EPC colonies. They also found that this 
subset of T cells enhances EPCs differentiation and angio-
genesis, resulting in neovascularization in vivo.
  In summary, a universal single or complex EPCs marker 
still remains to be identified, showing the heterogeneous of 
endothelial precursors. As a result, both different surface 
markers and culture properties have been used to define 
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KINETICS OF EPCs FOR POSTNATAL NEOVASCU-
LARIZATION 
Mobilization 
  Recruitment of EPCs from the BM quiescent niche has 
been found to be associated with the activation of proteinases 
such as elastase, cathepsin G, and matrix metalloproteinases 
(MMPs) [40]. These enzymes proteolytically cleave the ex-
tracellular matrix- or cell membrane-bound molecules re-
sponsible for EPCs’ adhesive bonds on BM stromal cells 
(Fig. (1)). These cells express membrane-bound Kit ligand 
(mKitL), which binds to the EPCs membrane receptor c-kit 
when the ligand is in its soluble form (sKitL). MMP-9 prote-
olytically cleaves mKitL to sKitL, which then interacts with 
the EPCs c-kit receptor to conduct the signal essential for 
BM-EPCs differentiation and migration to the peripheral 
blood (PB) [41] (Fig. (1)). One of the models used in study-
ing the recruitment of BM hematopoietic EPCs use BM cell 
suppression by cytotoxic agents. This suppression does not 
affect hematopoietic stem cells in the G0 phase of the cell 
cycle. Therefore, these cells may serve as a cell population to 
reconstitute hematopoiesis and EPCs release. The introduc-
tion of cytotoxic suppression in the BM of MMP-9
+/+ and 
MMP-9
-/- mice resulted in poor recruitment and differentia-
tion of hematopoietic cells only in the latter group of animals 
[40]. Treatment of MMP-9
+/+ mice with VEGF, stromal-
derivedfactor-1(SDF-1), and granulocyte colony-stimulating 
factor (G-CSF) caused a marked increase in the concentra-
tion of plasma sKitL compared with untreated animals [40]. 
The results of this experiment proved that VEGF, SDF-1, 
and G-CSF play significant roles in the induction of MMP-9 
precursor biosynthesis, secretion, and further mobilization of 
BM-EPCs to the PB [41-44] (Fig. (1)). 
Growth Factors that Effect EPCs Function 
  SDF-1 and VEGF have been considered crucial in the 
differentiation and migration of EPCs [41-44]. Increased 
plasma levels of SDF-1 and VEGF are eventually accompa-
nied by the mobilization of hematopoietic cells, among them 
EPCs, into the circulation (Fig. (1)). SDF-1 is a chemokine 
that binds specificially to the receptor designated as CXCR4 
[43]. This receptor is expressed on the surface of hema-
topoietic stem cells, including EPCs [43, 45]. The SDF-1 
acts as a key chemokine for the mobilization of EPCs and 
other progenitor cells from the BM compartment, e.g. by 
MMP-9-mediated cleavage of mKitL [46-48] (Fig. (1)). 
SDF-1 further mediates the recruitment of progenitor cells 
along hypoxic gradients and towards surface-adherent plate-
Fig. (1). Mobilization, recruitment, and differentiation of human, bone marrow-derived angiogenic progenitor cells.  
Hemangioblast, originated from hematopoietic cell, is resident in bone marrow niches, in a quiescent state. The stimulation by circulating 
cytokines induces the activation of matrix metalloproteinase-9 (MMP-9) through an Akt, nitric oxide dependent pathway. MMP-9 promotes 
the transformation of membrane bound Kit-ligand to a soluble Kit-ligand. This activation is followed by detachment of early c-Kit+ progeni-
tor cells from the bone marrow stromal niche and their subsequent movement to the vascular zone of the bone marrow. An important regula-
tion is VEGF and SDF-1, which binds to its receptor VEGFR-2 and CXCR4, respectively, thus mediating further maturation of the cascade 
hemangioblast-angioblast-early endothelial progenitor cells (EPC)-late EPCs. Bone marrow-derived EPCs are of hematopoietic origin and 
possibly derive from the hemangioblast. These early progenitors (CD133
+/CD34
+/VEGFR-2
+/CD14
-) represent a small population with pro-
liferative potential, capable to give rise to late endothelial outgrowth. Cells of myeloid origin (CD14
+) may also trans-differentiate into endo-
thelial cells and secret angiogenic factors, but their proliferative potential is limited and they did not generate a stable late outgrowth. 278 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Imanishi et al. 
lets after artrial injury [46-48]. Hristov et al. [49] revealed 
that blocking CXCR4 significantly reduced the adhesion of 
EPCs after arterial wire-injury in vivo. Additionally, SDF-1 
mediated migration of isolated EPCs, enhanced their matrix 
arrest when acting as a soluble chemokine, and was further 
secreted by activated platelets and SMCs after arterial wire-
injury [49, 50]. Within the clinical context, a dysregulation 
of the CXCR4 signaling in EPCs from patients with stable 
chronic coronary artery disease has been described [51]. 
Thus, the role of CXCR4 in EPCs biology appears to be 
moreuniversal. Recent data has provided evidence for VEGF 
autocrine action in hematopoietic cells, including apoptosis 
protection and survival effect [42]. Granulocyte macrophage 
colony-stimulating factor (GM-CSF) is also proposed as a 
possible candidate for EPCs function regulation [52]. In a 
study performed by Cho et al., recombinant GM-CSF was 
abletomobilizeEPCs and accelerated the re-endotheliazation 
process in hypercholesterolemic rabbits [52]. 
MECHANISMS OF CELLULAR SENESCENCE 
Phenotype and Pathways 
  Cellular senescence is originally described as the finite 
replicative lifespan of human somatic cells in culture. Senes-
cent cells remain viable, but they do not respond to mito-
genic stimuli and their morphological characteristics and 
function change dramatically [53-58]. They lose their origi-
nal shape, their volume increases, and they acquire a flat-
tened cytoplasma (“fried egg” appearance) [59, 60]. These 
changes are accompanied by alterations in nuclear structure, 
gene expression, protein processing, and metabolism [58, 
59]. These phenotypic changes of senescent cells are not 
observed in quiescent cells and have been implicated in ag-
ing and age-associated disease [61]. More recent data have 
shown that cells can enter senescence rapidly, independently 
of the number of cell divisions, in response to various 
physiological stresses (radiation, oxidative stress, lack of 
nutrients, DNA damage, and so on) [62-65]. This type of 
senescence has been termed stress-induced premature senes-
cence [66].  
  Although initially believed to be a cell-culture phenome-
non, cellular senescence recently was observed in vivo as 
well [67, 68]. The most common means of detecting cellular 
senescence is by colorimetric detection of -galactosidase in 
cells under mildly acidic (pH 6.0) conditions, in contrast to 
the more strongly acidic conditions (pH 4.0) normally re-
quired to detect endogenous lysosomal -galactosidase activ-
ity [69]. Other biomarkers include increased expression of 
p53, p21, and p16 [70-73]. 
  Senescence is a fundamental cellular program that paral-
lels that of programmed cellular death (apoptosis). Both mo-
lecular mechanisms restrict cellular proliferation. The reason 
a cell is driven to apoptosis versus senescence is not yet 
known [74-78]. The degree of stress [75] and cell-cycle 
phase [74] seem to be determining factors (eg, higher doses 
of oxidative stress induce apoptosis, whereas lower and long-
acting doses induce senescence). Moreover, apoptosis ap-
pears to occur more easily in senescent endothelial cells, yet 
seems to be blocked in other senescent cell types [78]. At the 
same time, factors involved in senescence signaling, such as 
p53, are also involved in apoptosis regulation through inter-
action with the BCL2 family of proteins [79]. In any case, 
cellular senescence as a biological mechanism, as well as the 
role that senescence has in the living organism, is, in contrast 
to apoptosis, not well understood. 
Telomeres and Telomerase 
  Significant progress has been made in our understanding 
of the mechanisms underlying cellular senescence. One 
widely discussed hypothesis of senescence is the telomere 
hypotheis[80]. Telomeres are non-nucleosomal DNA/protein 
complexes located at the ends of chromosomes that serve as 
protective caps and act as the substance for specialized repli-
cation mechanisms [81-83]. As a consequence of semicon-
servative DNA replication, the extreme terminals in succes-
sive shortening DNA replication, the extreame terminals of 
the chromosomes are not duplicated completely, resulting in 
successive shortening of the telomeres with each cell divi-
sion. Critical telomere shortening is thought to trigger the 
onset of cellular senescence. Thus, telomere shortening has 
been proposed to act as a mitotic clock that ptevents unlim-
ited proliferation of human somatic cells. However, te-
lomeres are also involved in stress-induced premature senes-
cence. It seems that this second pathway initiates not because 
of shortening, but because of changes in telomere structure 
(ie, alterations in the T loop and single-stranded overhang) 
[84, 85]. Thus both telomere length and structural integrity 
are necessary for proper chromosome function and avoid-
ance of DNA damage response and its consequent triggering 
of senescence. 
  Telomerase is a cellular reverse transcriptase which cata-
lyzes the synthesis and extension of telomeric DNA. Telom-
erase activity is consistently expressed in germline cells and 
in the majority of malignant tissue cells and is repressed in 
most human normal somatic cells. Strikingly, however, te-
lomerase activation is expressed in a highly regulated man-
ner in certain somatic cell populations, such as lymphocytes 
and hematopoietic stem cells. Studies on telomerase regula-
tion in normal somatic cells have focused on expression of 
the two essential components of telomerase, human telom-
erase RNA template (hTER) and human telomerase reverse 
transcriptase (hTERT). There is a good correlation between 
the expression of hTERT mRNA and the presence of telom-
erase activity in extracts from tissue culture and normal and 
cancer tissues, whereas hTER is expressed constitutively in 
both cancer and normal cells, irrespective of the status of 
telomerase expression. The hTERT enzyme not only pro-
duces telomeric repeats that elongates telomeres, but also 
prevents alterations in telomere structure, protecting the te-
lomere cap [86-88]. Early studies reported that telomerase 
activity was detected in cancer cells and stem cells but not in 
normal somatic cells [89, 90]. However, increasing evidence 
has suggested that telomerase activity regulates cell prolif-
eration in normal somatic cells by telomere lengthening or 
telomere length-independent mechanisms [91, 92]. Human 
endothelial cells and VSMCs express telomerase activity, but 
the activity declines with in vitro aging due to a decrease of 
hTERT, leading to telomere shortening and cellular senes-
cence [93, 94]. In fact, induction of telomerase extends the 
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gesting a critical role of telomere and telomerase in vascular 
senescence.  
FUNCTIONAL AND ANTIOXIDATIVE CAPACITY 
OF EPCS 
  To contribute to tissue repair, EPCs and stem cells in 
general, have to be equipped with antioxidative defence sys-
tem to survive, in necrotic and ischemic tissues. Interest-
ingly, a high resistance to oxidative stress has been consid-
ered a characteristics feature of stem cells [97, 98]. Protec-
tion against oxidative stress by ROS is accomplished by a 
complex defense system composed of several antioxidative 
enzymes that reduce the damaging effects of ROS [99]. The 
most vulnerable organelles to oxidative stress are the mito-
chondria, because of the permanent potential for the produc-
tion of superoxide anions. Superoxide anions are converted 
to hydrogen provided by superoxide dismutases, whereas 
hydrogen peroxide is detoxified by the enzymes by catalase 
and glutathione peroxidase. Because of the localization of 
MnSOD and GPx-1 in the matrix of the mitochondria, in 
close proximity to the production of ROS by the electron 
transport chain, these two enzymes are believed to be the 
primary antioxidant defense systems in the mitochondria. 
What is the specific mechanism by which ROS affect mobil-
zation and progenitor cell differentiation toward the endothe-
lial lineage? Recently, two in vivo studies demonstrated that 
EPCs express high levels of MnSOD and GPx-1 [15, 16]. 
Galasso et al. [100] have addressed the role of GPx-1 for the 
functional capacity of EPCs in vivo. They investigated 
ischemia-induced neovascularization in GPx-1deficient mice 
and assessed the number and functional activity of EPCs. 
GPx-1-deficient mice showed a reduced blood flow recovery 
after hindlimb ischemia compared with their wild type. This 
was accompanied with reduced EPCs levels in response to 
the functional capacity of EPCs to migarate and promote 
angiogenesis in vivo. These findings support the knowledge 
that EPCs require antioxidative enzymes, especially GPx-1, 
for their functional capacity. However, is the reduction of 
EPCs in GPx-1-deficient mice caused by increased cell death 
or decreased differentiation or mobilization? Galasso et al.
[100] demonstrated that EPCs derived from GPx-1-deficient 
mice show increased apoptosis sensitivity and decreased 
expression of Flk-1 are involved in the reduction of EPC 
levels from GPx-1-deficient mice. However, a reduced Flk-1 
expression was demonstrated before and after ischemia, sup-
porting the hypothesis that interfering with the antioxidant 
defense system of cells may also influence differentiation. 
Although the precise molecular mechanisms are unknown so 
far, one may speculate that the reduced bioavailability of NO 
reported for the GPx-1-deficient mice may contribute to the 
phenotype of the mice [101]. It is also important to note that 
eNOS-deficient mice show a similar impaired capacity to 
mobilize EPCs combined with a systemic dysfunction of 
isolated EPCs [102, 103]. The finding that GPx-1 expression 
is essential for EPC functions may also have clinical implica-
tions, given that patients with chronic heart failure [104] and 
with type 2 diabetes [105] showed a downregulation of GPx-
1. This in turn may contribute to the reduced EPC numbers 
and function in patients with CAD and severe heart failure 
[106]. However, other antioxidative enzymes such as super-
oxide dismutase and catalases are also downregulated in 
these patients [105, 106]. In addition, some controversy does 
exist about the effects of oxidant stress on EPCs. Ingrum et
al. [17] reported that clonogenic cord and adult blood-
derived EPCs are sensitive to oxidant stress. Furthermore, 
EPCs treated with oxidants undergo increased apoptosis and 
decreased tube formation via apoptosis signal-regulating 
kinase 1 (ASK1) activation. Thus, it seems mandatory to 
emphasize the importance of designing therapeutic strategies 
to protect EPCs against oxidant stress to enhance new vessel 
formation. 
EFFECTS OF ATHEROGENIC FACTORS ON EPCS 
SENESCENCE 
  Clinical studies clearly demonstrate that high EPCs levels 
are associated with reduced cardiovascular event rates under-
lying the vasculoprotective action of EPCs [107, 108]. The 
rejuvenation of the endothelium by circulating EPCs may 
represent a novel approach in the prevention of atheroscle-
rotic disease. However, limitations in therapy may come 
from the negative influence of cardiovascular risk factors, 
which are apparently overwhelming the organism’s repair 
mechanisms, bringing the equilibrium between vascular re-
pair and injury out of balance (Fig. (2)). Cardiovascular risk 
factors negatively influence EPCs number and function, 
whereas vasculoprotection is at least in part mediated by 
functional active EPCs. Therefore, EPCs may present a cel-
lular risk marker, integrating the positive and negative me-
diators affecting the endothelial monolayer. Multiple factors 
seem to be involved in the aging-associated deterioration of 
EPCs quantity and function. The chronic exposure to cardio-
vascular risk factors continuously damages endothelial cells 
and requires their intensive replacement. Conversely, cardio-
vascular risk factors possibly affect EPCs mobilization, inte-
gration in injured vascular sites, and angiogenic capacity 
(Fig. (2)). Recent studies have underlined the detrimental 
effects of type 1 and 2 diabetes on EPCs function [5, 109]. 
Loomans et al. [109] have demonstrated that the media from 
EPCs culture of type 1 diabetic patients not only possess 
evidence of reduced angiogenic capacity, but also contain an 
inhibitor for in vitro tube formation. Tepper et al. [5] re-
ported that the proliferation and tube formation of EPCs 
were impaired in patients with type 2 diabetes compared 
with normal subjects. In both studies, decreased number and 
dysfunction of EPCs was inversely related to the levels of 
hemoglobin A1c, implying that the degree of glycemic dys-
regulation was associated with EPCs pathophysiology. Al-
though these studies have clarified an adverse effect of DM 
on the functional activity of EPCs, the underlying mecha-
nisms remain unsolved. The EPCs dysfunction may also be 
result of their accelerated senescence. We showed that hy-
perglycemia (HG) increases the rate of EPCs senescence, 
which effect is inhibited by an inhibitor p38 MAPK, 
SB203580 [110]. We also have demonstrated that high glu-
cose (HG) levels can accelerate the p38 MAPK pathway in 
EPCs [110]. Seeger et al [111] have demonstrated that the 
redunction of EPCs induced by high glucose (HG) in vitro is 
associated with a profound upregulation of p38 mitogen ac-
tivated protein kinase (MAPK) phosphorylation and is com-
pletely blocked by p38 inhibitors. Furthermore, EPCs culti-
vated from patients with CAD show an increased p38 phos-
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jects. Interestingly, they have shown that HG further aug-
ment the phosphorylation of the p38 downstream kinase 
stress-activated kinase (MSK)1 and the transcription factor 
camp-responsive element-binding protein (CREB). Several 
studies demonstrate that p38 MAPK blockade inhibition is 
associated with increased angiogenesis [112-114]. Because 
NAD(P)H oxidase activation promotes p38 MAPK phos-
phorylation [111], it is tempting to speculate that increased 
p38 MAPK phosphorylation may represent an additional 
potential pathway whereby NAD(P)H oxidase may alter 
EPCs function in DM. Therefore, p38 MAPK inhibitors 
and/or NAD(P)H inhbition might be a promising tool to 
augment the yield of ex-vivo-expanded EPCs for cell ther-
apy, specially for the patients with DM. In this context, Sor-
rentino et al. [115] have demonstrated that short-term in vivo
rosiglitazone treatment in diabetic subjects reduced EPCs 
NAD(P)H oxidase activity and restored NO availability, 
suggesting that PPAR- agonist exerts a direct on NAD(P)H 
oxidase in diabetic EPCs. Of note, in vitro treatment with the 
PPAR- agonist pioglitazone prevented oxidative stress-
induced apoptosis in human EPCs, further suggesting a role 
of PPAR- for EPCs function [116]. We have also shown 
that pioglitazone reduces Ang II-induced acceleration of 
senescence in EPCs [117]. Collectively, therapeutic interven-
tions that improve vascular activity in EPCs by PPAR- ago-
nists may have tremendous potential for the treatment of 
cardiovascular diseases. 
  The number of circulating EPCs in patients with CAD 
has been shown to decline with increasing age [3]. Further-
more, following coronary artery bypass grafting, EPCs mobi- 
lization is significantly impaired in older individuals com-
pared with younger patients [118]. Besides changes in EPCs 
levels, the function of EPCs from older individuals also ap-
pear to be disrupted, based on in vitro examination of EPCs 
survival, proliferation, and migration [3, 119]. These results 
strongly suggest that age is an important determinant of 
EPCs function and further support the hypothesis that 
changes in EPCs function with age contribute to the impair-
ment of cardiovascular repair mechanisms in the aging host. 
The age-associated impairment of cardiac angiogenic capac-
ity in older mice, estimated as neovascularization of cardiac 
allografts, can be restored by implantation of BM-derived 
EPCs from young adult animals [120]. Progression of athe-
roscleorsis in apolipoprotein E
-/- mice with persistent hyper-
cholesterolemia seems delayed by chronic administration of 
BM-derived progenitor cells from young mice [120]. This 
treatment was much less effective when donors were older 
animals with atherosclerosis, indicating that progressive age-
dependent reduction in EPCs may accelerate the develop-
ment of atherosclerosis, particularly in the presence of hy-
percholesterolemia [120].  
  Reduced levels of angiogenic and mobilizing cytokines 
have been related to age-dependent impairment of EPCs mo-
bilization in vivo. Indeed, vascular endothelial growth factor 
(VEGF) and NO production have been reported to decrease 
with age [118-120]. Specifically, eNOS expression and sub-
sequent NO production are crucial in EPCs mobilization 
(Fig. (1)) [121, 122]. In this context, eNOS is a central 
downstream mediator in VEGF-signaling pathways [123-
125]. Moreover, we and others have shown that ox-LDL,   
Fig. (2). Oxidative stresses on endothelial progenitor cells (EPCs) in cardiovascular diseases. 
EPCs repair cardiovascular damage. Oxidative stress caused by dyslipidemia, diabetes mellitus, or hypertension interferes with the ability of 
EPCs proliferation, differentiation, and mobilization in bone marrow. Oxidative stress also induces EPCs senescence. These negative effects 
of oxidative stress on EPCs number and function bring the equilibrium between cellular repair and injury out of balance, resulting in the 
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which accumulates with age, also suppresses eNOS expres-
sion and impairs EPCs survival and function [126, 127]. We 
showed that ox-LDL accelerates the onset of EPCs senes-
cence, which leads to impairment of proliferative capacity 
and network formation [127]. However, the mechanisms by 
which ox-LDL accelerates the onset of EPCs senescence 
remain unclear. We also demonstrated that, in the presence 
of VEGF, ox-LDL reduces the number of adherent EPCs 
through dephosphorylation of the Akt kinase on Ser
473 in 
EPCs [128]. Dimmeler et al. [129] showed that VEGF, as 
well as statins, induces EPCs differentiation via the PI3-
K/Akt pathway, as showed by the inhibitory effect of phar-
macological PI3-K blockers or the overexpression of a 
dominant negative Akt construct. Interestingly, Breitschopf 
et al. [130] showed that a dominant-negative Akt signifi-
cantly reduced telomerase activity in HUVECs. Therefore, it 
is possible that ox-LDL accelerates the onset of EPCs senes-
cence through telomerase inactivation, which may be related 
to inactivation.  
POTENTIAL ROLE OF OXIDATIVE STRESS IN 
EPCS SENESCENCE IN ACTIVATION OF RENIN-
ANGIOTENSIN SYSTEM 
Ang II and Oxidative Stress 
  Ang II increases oxidative stress, inflammation, and al-
ters endothelial function [131, 132]. The principle sources of 
ROS in the human vasculature is NAD(P)H oxidase, acti-
vated by a number of proatherogenic stimuli including Ang 
II. Overall NAD(P)H oxidase activity in cells is achieved by 
several components. These included cell-membrane-associ-
ated p22phox and gp91phox (or gp91phox [nox2] homo-
logues, nox1 and nox4), as well as cytosolic p47phox and 
p67phox [132]. Vascular NAD(P)H oxidase is upregulated 
by vasoactive factors, stretch, shear stress and pulsatile strain 
[132]. At low concentrations ROS serve a physiological role 
as signalling molecules involved in endothelial function and 
vascular contractility [131]. However, pathological increases 
in ROS results in a plethora of effects that damage the vessel 
wall [133].  
Ang II and EPCs Senescence 
  We have shown that in animal models of hypertension, as 
well as in subjects with essential hypertension, EPCs become 
precociously senescent and dysfunctional [134]. Higher 
blood pressure is associated with lower EPCs levels in the 
general population [135], and in diabetic subjects [136]. Hy-
perreactivity of the renin-angiotensin system (RAS) has been 
recognized as one link between hypertension and altered 
EPCs biology. Bahlmann et al. [136] documents that angio-
tensin receptor antagonists increase the number of EPCs in 
patients with type II diabetes mellitus. This effect seems to 
be a class effect, because they have demonstrated it with 
standard doses of 2 long acting ARBs (olmesartan or irbesar-
tan). In contrast, in patients treated with standard antihyper-
tensives, they did not observe any effects of EPCs. Ramipril 
is an angiotensin-converting enzyme (ACE) inhibitor used to 
reduce RAAS activation in patients with stable CAD. Min et
al. [137] showed that increased numbers of EPCs could be 
cultured from ramipril-treated patients with stable CAD and 
that ACE inhibition resulted in improved functional proper-
ties like adhesion, proliferation, migration, and in vitro vas-
culogenesis assay, independent of any impact on blood pres-
sure. These results show that EPCs are sensitive to Ang II 
signalling and that this should indeed impact on number and 
function. Our group has shown that Ang II increases the rate 
of senescence of EPCs and that this appears to be a conse-
quence of its ability to stimulate expression of gp91phox and 
thus O2
- formation [138]. In addition, we have demonstrated 
that the ability of Ang II to induce senescence also involves 
the suppression of telomerase [138]. Our group also noticed 
an expected increase in formation of a marker of oxidative 
stress-peroxynitrite, which is formed of O2
- with NO in the 
Ang II-treated EPCs [138]. Increased O2
- production is a 
feature of Ang II-dependent hypertension [139]. Thus, under 
conditions of Ang II excess, Ang II most likely contributes to 
the decline in formation of the vascular endothelium at least 
in part by the mechanisms via Ang II-induced EPCs senes-
cence (Fig. (3)). On the other hand, it has been demonstrated 
that Ang II and angiotensin peptides promote hematopoietic 
progenitor cell proliferation and hematopoietic recovery after 
radiation therapy and chemotherapy [140]. Murohara et al
reported that the Ang II-AT1 receptor pathway plays an im-
portant role in angiogenesis associated with ischemia and 
tumor growth [141, 142]. These results appear to be contra-
dictory to protective effects of RAS suppression on EPCs 
function. Recent studies suggested that the intracellular re-
dox state is a critical modulator of the balance between self-
renewal and differentiation in dividing precursor cells and 
that anti-oxidant may preserve their stemness [143]. It is 
plausible that a reduction in oxidative stress resulted in resto-
ration of the impaired faction of EPCs in spontaneous hyper-
tensive rats as well as patients with metabolic disorders, al-
though it remains to be determined whether RAS inhibition 
stimulates EPCs function under physiological conditions in 
healthy subjects.  
PHARMACOLIGIC MODULATIONS ON EPCS SE-
NESCENCE 
HMG-CoA Reductase Inhibitors (Statins) 
  Pharmacologically, statins have been shown to enhance 
EPCs-mediated angiogenesis in models of ischemic tissue 
injury. In vivo, statin treatment increases the numbers of cir-
culating EPCs and enhances both neovascularization in cor-
neal assays and reendotheliazation of injured vessels, pro-
moting incorporation of labeled BM-derived cells into these 
vessels [144-146]. Mechanistically, statin treatment in vitro
appears to inhibit EPCs senescence, via induction of te-
lomere repeat binding factor-2, which inhibits induction of 
the DNA damage checkpoint-kinase 2 [147]. Simvastatin 
activates the serine-threonine kinase Akt in endothelial cells, 
promoting endothelial cell survival and migration [148]. Akt 
also acts downstream of VEGF and may therefore represent 
a key regulator of VEGF-mediated neovascularization [149]. 
Thus, these data suggest that statin therapy may constitute an 
important approach in the development of strategies to im-
prove EPCs survival and function and to improve cardiac 
repair pathways in the aging population. Indeed, the TOP-
CARE-AMI clinical trial demonstrated that the treatment of 
ex vivo cultured blood-derived progenitor cells with atorvas-
tatin was found to be safe and potentially effective for the 
enhancement of cardiac regeneration [150]. 282 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Imanishi et al. 
Ang II Receptor Blockers (ARBs) 
  ARBs have been shown to be antioxidant and vasopro-
tective through downregulation of vascular NAD(P)H oxi-
dase expression in patients with CAD [151]. Treatment with 
either an ACE inhibitor or ARB lowered levels of vascular 
superoxide. Bahlmann et al. [136] reported that ARBs in-
crease the number of EPCs in patients with type II diabetes 
mellitus. Our group reported that Ang II accelerates EPCs 
senescence  via the AT1 receptor and through induction of 
oxidative stress [138], (Fig. (3)). Exposure of cultured EPCs 
to Ang II significantly accelerated the rate of senescence 
compared with a control and impaired proliferative activity. 
We also showed that Ang II-induced EPCs senescence was 
significantly inhibited by pretreatment with either valsartan 
or superoxide dismutase (SOD) [138]. Ang II also signifi-
cantly diminished telomerase activity, and this effect was 
significantly reduced by pretreatment with either an AT1 
receptor antagonist, valsartan, or SOD [138]. In addition, 
Yao et al. [152] reported that EPCs colony formation was 
markedly lower in SHR-SP than in WKY rats. Losartan im-
proved the reduced colony formation with inhibition of oxi-
dation from SHR-SP by reducing expression of gp91phox, 
p22phox, and p47phox. Trichlormethiazide did not affect the 
reduced colony formation in EPCs. Thus, EPCs function was 
altered in Ang II-dependent hypertension with oxidative 
stress. These data indicate that EPC has an Ang II-generating 
system that accelerates senescence of EPCs and may directly 
contribute to vascular injury in hypertension. 
Estrogens 
  No direct studies of effect of estrogen therapy on EPCs in 
humans are available, but increased blood estrogen levels in 
women do correlate with numbers of circulating EPCs [130]. 
In an animal carotid injury model, estradiol treatment 
showed stimulatory effects on EPCs mobilization, prolifera-
tion, mitogenic and migratory activity, as well as inhibited 
EPCs apoptosis [123]. Mechanistically, we have demon-
strated that estrogen augments differentiation and delays the 
onset of the senescence in BM-EPCs from SHR/Izm, accom-
panied with telomerase activation via up-regulation of 
hTERT mRNA in a PI3-K/Akt dependent manner [153]. 
Importantly, the inhibition of BM-EPCs senescence by es-
trogen  in vitro resulted in improved functional activity of 
BM-EPCs [153]. We showed that 17-estradiol dose-
dependently inhibited the senescence of cultured human PB-
MNCs by increasing the catalytic activity of telomerase 
[154]. We also showed that telomerase activity in EPCs is 
upregulated by treatment with 17-estradiol. Furthermore, 
we have demonstrated that this activation accompanied 
upregulation of the hTERT mRNA [154]. We speculated that 
estrogen delays the onset of senescence through telomerase 
activation, which may be related to estrogen-induced upregu-
lation of the expression of hTERT. However, with regard to 
senescence, the structure of the telomere appears at least as 
important as its absolute length, in relation to telomere func-
tion [155]. In addition, we can not rule out the possibility 
that a telomere-independent mechanism regulates replicative 
senescence. Further studies are required to elucidate the 
mechanisms underlying the inhibitory effects of 17-
estradiol on senescence in EPCs. Importantly, the inhibitory 
effects of 17-estradiol on EPCs senescence may not be of 
only a beneficial nature. Telomere shortening is probably 
one of the body’s anticancer mechanisms, and estrogen is 
considered to be a potentially cancer-promoting substance. 
Indeed, estrogens increase the incidence of various malig-
nancies [156]. It is tempting to speculate that the induction of 
neoplasia during estrogen treatment might be dependent on 
the effects of EPCs. 
CONCLUSIONS AND IMPLICATIONS 
  Recent data show that the vascular regenerative potential 
of patients with cardiovascular risk factors may be impaired 
Fig. (3). Potential mechanisms of Ang II-induced EPCs senescence.  
Ang II stimulates gp91
phox expression, a subunit of NADPH oxidase, via the angiotensin type 1 (AT1) receptor, which leads to the increase in 
superoxide (O2
-). Furthermore, peroxynitrite is formed form the inteaction of O2
- with nitric oxide (NO). Both superoxide and peroxynitrite 
inactivate telomerase activity, which induces the impairment of telomere structure integrity, resulting in senescence. Endothelial Progenitor Cells Dysfunction and Senescence  Current Cardiology Reviews, 2008, Vol. 4, No. 4    283
as a consequence of reduced number and function of circu-
lating EPCs that can support endothelial maintenance and 
ischemia-induced neovascularization. Recent studies have 
demonstrated a critical role of oxidative stress in the EPCs 
dysfunction. Notably, oxidative stress-induced EPCs prema-
ture senescence is involved in this process. Autologous 
transplatation of progenitor cells that are affected by cardio-
vascular risk factors, may not only be hampered by a dys-
functional nature of these cells but in fact may stimulate 
proatherogenic mechanisms, such as monocyte recruitment 
or vascular smooth muscle cell proliferation. Therefore, at-
tention should be paid to transplantation of autologous BM 
cells or circulating EPCs not to promote atherosclerosis. The 
therapeutic goal must be the rebalancing between endothelial 
injury and repair. In the future, the use of a vascular repair 
index may be important for choosing therapy strategies with 
a maximized benefit for the patient. With this knowledge in 
mind, we need to search for more effective proregenerative 
therapeutic strategies not only for neoangiogenesis but, more 
importantly, for regeneration of the dysfunctional vascular 
wall, which represents the common trunk for all cardiovascu-
lar diseases.  
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